AS1517499
Based on 55 publication(s) in Google Scholar
AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC50 of 21 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.99%
- No. CAS: 919486-40-1
- Fòrmula: C20H20ClN5O2
- Peso molecular:397.86
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
JAK/STAT Compound Library
HY-L008
-
Kinase Inhibitor Library
HY-L009
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) AS1517499
More- Cancer Cell. 2025 Jul 29:S1535-6108(25)00313-7. [Abstract]
- Cancer Cell. 2025 Feb 10;43(2):269-291.e19. [Abstract]
- Immunity. 2026 May 29:S1074-7613(26)00180-9. [Abstract]
- Cell Mol Immunol. 2022 Nov;19(11):1263-1278. [Abstract]
- Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]
- Cell Death Differ. 2021 Sep;28(9):2728-2744. [Abstract]
- Acta Pharm Sin B. 2023 Jun;13(6):2645-2662. [Abstract]
- Compos B Eng. 2023 Jan.
- Adv Sci (Weinh). 2026 Apr;13(24):e20739. [Abstract]
- Theranostics. 2024 May 13;14(7):3014-3028. [Abstract]
- Theranostics. 2021 Jan 1;11(3):1192-1206. [Abstract]
- Allergy. 2025 Oct 22. [Abstract]
- Redox Biol. 2024 May:71:103100. [Abstract]
- J Exp Med. 2018 Aug 6;215(8):2175-2195. [Abstract]
- Cell Death Dis. 2026 Jun 10. [Abstract]
- Cell Death Dis. 2026 Jan 3. [Abstract]
- Genes Dis. 2026 Jan 20.
- Cell Commun Signal. 2025 Oct 10;23(1):431. [Abstract]
- Dev Cell. 2025 May 15:S1534-5807(25)00287-4. [Abstract]
- Cancer Immunol Res. 2020 Nov;8(11):1426-1439. [Abstract]
- Oncogene. 2026 Apr 29. [Abstract]
- Cell Rep. 2026 Jun 4;45(6):117519. [Abstract]
- Cell Rep. 2024 Jun 18;43(7):114364. [Abstract]
- Allergol Int. 2026 Feb 17.
- Phytother Res. 2026 Apr 27. [Abstract]
- Ecotoxicol Environ Saf. 2024 Aug 1:283:116793. [Abstract]
- Cell Biol Toxicol. 2023 Dec;39(6):2821-2839. [Abstract]
- Front Immunol. 2021 Jul 5;12:683249. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117120. [Abstract]
- J Ethnopharmacol. 2026 Oct 28:369:121888. [Abstract]
- Inflamm Res. 2025 Mar 17;74(1):54. [Abstract]
- Inflamm Res. 2024 Sep;73(9):1511-1527. [Abstract]
- CNS Neurosci Ther. 2025 Aug;31(8):e70572. [Abstract]
- Respir Res. 2017 Sep 20;18(1):174. [Abstract]
- Int J Mol Sci. 2022 Nov 5;23(21):13572. [Abstract]
- Int Immunopharmacol. 2026 Jan 1;168(Pt 1):115747. [Abstract]
- Int Immunopharmacol. 2024 Sep 27;142(Pt B):113258. [Abstract]
- Eur J Pharmacol. 2023 Aug 15:953:175860. [Abstract]
- Molecules. 2023 Apr 24;28(9):3682. [Abstract]
- J Cell Mol Med. 2020 Sep;24(17):9646-9657. [Abstract]
- Sci Rep. 2019 Nov 14;9(1):16781. [Abstract]
- Food Sci Nutr. 2026 Feb 15;14(2):e71561. [Abstract]
- Food Sci Nutr. 2025 Nov 17;13(11):e71234. [Abstract]
- Cell Signal. 2020 Aug;72:109628. [Abstract]
- Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L888-L899. [Abstract]
- J Immunol. 2021 Mar 1;206(5):963-977. [Abstract]
- J Immunol. 2021 Jan 1;206(1):118-131. [Abstract]
- Front Oncol. 2022 May 5;12:823377. [Abstract]
- Mol Immunol. 2026 May 23:195:198-208. [Abstract]
- PLoS One. 2026 Apr 9;21(4):e0341313. [Abstract]
- Allergy Asthma Clin Immunol. 2022 Feb 17;18(1):12. [Abstract]
- Biochem Biophys Rep. 2023 Dec 16:37:101608. [Abstract]
- Iran J Immunol. 2024 Sep 25;21(3). [Abstract]
- Patent. US20240307497A1.
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
Flow Cytometry
-
Cell Proliferation/Viability Assay
-
WB
-
WB
-
RT-PCR
Actividad biológica
|
STAT6 21 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| T-cell | IC50 |
2.3 nM
Compound: 2t, AS1517499
|
Effect on differentiation of C57BL/6 mouse T cells assessed as inhibition of IL4 production
Effect on differentiation of C57BL/6 mouse T cells assessed as inhibition of IL4 production
|
[PMID: 17071093] |
AS1517499 shows potent STAT6 inhibition with an IC50 value of 21 nM, and also inhibits IL-4-induced Th2 differentiation of mouse spleen T cells with an IC50 value of 2.3 nM and without influencing T-helper cell 1 (Th1) differentiation induced by IL-12. AS1517499 selectively inhibits Th2 differentiation without affecting Th1 differentiation[1].
In cultured human BSM cells, IL-13 (100 ng/mL) causes a phosphorylation of STAT6 and an up-regulation of RhoA, a monomeric GTPase responsible for Ca2+ sensitization of smooth muscle contraction: both events are inhibited by co-incubation with AS1517499 (100 nM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 919486-40-1
-
Appearance Solid
-
Peso molecular 397.86
-
Fòrmula C20H20ClN5O2
-
Color White to light brown
-
SMILES
O=C(C1=CN=C(NCCC2=CC=C(O)C(Cl)=C2)N=C1NCC3=CC=CC=C3)N
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (55)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases. [Abstract]2025 Jul 29:S1535-6108(25)00313-7. PMID: 40780215
AS1517499 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Jul 29:S1535-6108(25)00313-7. [Abstract]
CHI3L3 expression in neutrophils treated with DKK1 protein and/or AS1517499 (p-STAT6 inhibitor, 1 μM; 24-48 h) was detected by flow cytometry.
-
Cancer Cell
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. [Abstract]2025 Feb 10;43(2):269-291.e19. PMID: 39933899 -
Immunity
Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. [Abstract]2026 May 29:S1074-7613(26)00180-9. PMID: 42214327 -
Cell Mol Immunol
2022 Nov;19(11):1263-1278. PMID: 36180780 -
Nat Commun
Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma. [Abstract]2024 Jun 21;15(1):5292. PMID: 38906855
AS1517499 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]
Representative heatmaps for cell viability using MHH-ES-1 cells treated with indicated doses of compounds (AS1517499 (1-10 μM), SN-38 (3-30 μM)) for 2 days.
AS1517499 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 21;15(1):5292. [Abstract]
IB analysis of WCL from MHH-ES-1 cells treated with indicated compounds for 24 h. AS1517499, 5 μM; SN-38, 1 μM; etoposide, 10 μM.
-
Cell Death Differ
PP2Acα promotes macrophage accumulation and activation to exacerbate tubular cell death and kidney fibrosis through activating Rap1 and TNFα production. [Abstract]2021 Sep;28(9):2728-2744. PMID: 33934104 -
Acta Pharm Sin B
The suppression of cervical cancer ferroptosis by macrophages: The attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. [Abstract]2023 Jun;13(6):2645-2662. PMID: 37425043 -
-
Adv Sci (Weinh)
TGM2 Aggravates Acute Pancreatitis by Impairing Macrophage Efferocytosis Through Inhibition of the STAT6-GAS6 Axis. [Abstract]2026 Apr;13(24):e20739. PMID: 41703992 -
Theranostics
Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling. [Abstract]2024 May 13;14(7):3014-3028. PMID: 38773979
AS1517499 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 May 13;14(7):3014-3028. [Abstract]
AS1517499 (500 nM; 30 min) efficiently blocked IL-4-induced CAF activation and upregulation of POSTN in CAFs.
AS1517499 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 May 13;14(7):3014-3028. [Abstract]
AS1517499 (500 nM; 30 min) efficiently blocked IL-4-induced CAF activation and upregulation of POSTN in CAFs.
-
Theranostics
Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis. [Abstract]2021 Jan 1;11(3):1192-1206. PMID: 33391530 -
Allergy
Club Cells in Nasal Epithelial Repair: Insights From an IL-13-Induced Inflammatory Model. [Abstract]2025 Oct 22. PMID: 41123053 -
Redox Biol
IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. [Abstract]2024 May:71:103100. PMID: 38484644 -
J Exp Med
2018 Aug 6;215(8):2175-2195. PMID: 29970474 -
Cell Death Dis
Deficiency of G9a boosts muscle regeneration through IL13/Musclin-mediated crosstalk between macrophage and myofiber. [Abstract]2026 Jun 10. PMID: 42270589 -
Cell Death Dis
SOX4-STAT6-MTHFD2 axis drives hepatocellular carcinoma progression and treatment resistance. [Abstract]2026 Jan 3. PMID: 41484064 -
-
Cell Commun Signal
T cell receptor associated transmembrane adaptor 1 (TRAT1) modulates human Th17 and Treg responses via PI3-kinase and STAT dependent mechanisms. [Abstract]2025 Oct 10;23(1):431. PMID: 41074026 -
Dev Cell
Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages. [Abstract]2025 May 15:S1534-5807(25)00287-4. PMID: 40403724 -
Cancer Immunol Res
Blocking P2X7-Mediated Macrophage Polarization Overcomes Treatment Resistance in Lung Cancer. [Abstract]2020 Nov;8(11):1426-1439. PMID: 32933967 -
Oncogene
MS4A4A promotes macrophages M2 polarization via NF-κB /JAK-STAT6 axis, resulting GBM malignant progression. [Abstract]2026 Apr 29. PMID: 42056558 -
Cell Rep
IL-33/TGF-β/IL-4-induced bone marrow-derived DC9 subset promotes Th9 differentiation and allergic airway inflammation. [Abstract]2026 Jun 4;45(6):117519. PMID: 42247295 -
Cell Rep
Tonic type 2 immunity is a critical tissue checkpoint controlling autoimmunity in the skin. [Abstract]2024 Jun 18;43(7):114364. PMID: 38900635 -
-
Phytother Res
(+)-Matairesinol, Derived From Olive Oil, Enhanced T-Cell Anti-Tumor Immune via JAK3-STAT1 Signal and Synergized With Anti-PD-1 Efficacy. [Abstract]2026 Apr 27. PMID: 42037203 -
Ecotoxicol Environ Saf
Involvement of M2 macrophages polarization in PM2.5-induced COPD by upregulating MMP12 via IL4/STAT6 pathway. [Abstract]2024 Aug 1:283:116793. PMID: 39094453 -
Cell Biol Toxicol
The mtDNA-STING pathway plays an important role in both navitoclax- and S63845-induced autophagy and enhances cell death. [Abstract]2023 Dec;39(6):2821-2839. PMID: 37002446 -
Front Immunol
Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands+ Macrophages via Activating IL-4/STAT6/PD-L2 Signaling. [Abstract]2021 Jul 5;12:683249. PMID: 34290705 -
Biochem Pharmacol
Dual inhibition of EGR1/STAT3 transcriptional hubs suppresses macrophage-driven liver fibrosis: A multi-omics-guided drug repurposing strategy. [Abstract]2025 Oct:240:117120. PMID: 40623460 -
J Ethnopharmacol
"Shihu" promote T-cell immunity against breast cancer through bioactive constituent THMB enhancing JAK3-STAT1 signal. [Abstract]2026 Oct 28:369:121888. PMID: 42202911 -
Inflamm Res
2025 Mar 17;74(1):54. PMID: 40095032 -
Inflamm Res
Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain. [Abstract]2024 Sep;73(9):1511-1527. PMID: 39028491 -
CNS Neurosci Ther
IL-4-JAK1-STAT6 Pathway Mediates Electroacupuncture's Effect on Microglial M2 Polarization to Treat Inflammatory Bowel Disease With Comorbid Depression. [Abstract]2025 Aug;31(8):e70572. PMID: 40823702 -
Respir Res
IL-4-induced caveolin-1-containing lipid rafts aggregation contributes to MUC5AC synthesis in bronchial epithelial cells. [Abstract]2017 Sep 20;18(1):174. PMID: 28931396 -
Int J Mol Sci
HSD3B1 Expression Is Upregulated by Interleukin 4 in HT-29 Colon Cancer Cells via Multiple Signaling Pathways. [Abstract]2022 Nov 5;23(21):13572. PMID: 36362361 -
Int Immunopharmacol
Microbial metabolite tigloside alleviates osteoarthritis by repolarizing macrophages from M1 to M2 phenotype through Trafd1 destabilization and Trafd1-mediated NF-κB/STAT6 signaling pathways. [Abstract]2026 Jan 1;168(Pt 1):115747. PMID: 41192114 -
Int Immunopharmacol
Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation. [Abstract]2024 Sep 27;142(Pt B):113258. PMID: 39340991 -
Eur J Pharmacol
Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6 / NF-kappaB signaling pathway. [Abstract]2023 Aug 15:953:175860. PMID: 37331681 -
Molecules
Pulsatilla Saponins Inhibit Experimental Lung Metastasis of Melanoma via Targeting STAT6-Mediated M2 Macrophages Polarization. [Abstract]2023 Apr 24;28(9):3682. PMID: 37175092 -
J Cell Mol Med
MCTR1 enhances the resolution of lipopolysaccharide-induced lung injury through STAT6-mediated resident M2 alveolar macrophage polarization in mice. [Abstract]2020 Sep;24(17):9646-9657. PMID: 32757380 -
Sci Rep
Autocrine Production of Interleukin-34 Promotes the Development of Endometriosis through CSF1R/JAK3/STAT6 signaling. [Abstract]2019 Nov 14;9(1):16781. PMID: 31727934 -
Food Sci Nutr
Lycium barbarum Polysaccharide Alleviates Renal Damage in Mouse Sepsis by Regulating M1/M2 Macrophage Polarization. [Abstract]2026 Feb 15;14(2):e71561. PMID: 41700132 -
Food Sci Nutr
Octanoic Acid-Rich Enteral Nutrition Regulates Intestinal M1/M2 Macrophage Polarization via the PPARγ/STAT-1/STAT-6 Pathway to Alleviate Inflammatory Bowel Disease. [Abstract]2025 Nov 17;13(11):e71234. PMID: 41256230 -
Cell Signal
CD137 signaling induces macrophage M2 polarization in atherosclerosis through STAT6/PPARδ pathway. [Abstract]2020 Aug;72:109628. PMID: 32247042 -
Am J Physiol Lung Cell Mol Physiol
IL-4/IL-13 upregulates Sonic hedgehog expression to induce allergic airway epithelial remodeling. [Abstract]2020 May 1;318(5):L888-L899. PMID: 32130032 -
J Immunol
The Anti-Inflammatory Immune Response in Early Trichinella spiralis Intestinal Infection Depends on Serine Protease Inhibitor-Mediated Alternative Activation of Macrophages. [Abstract]2021 Mar 1;206(5):963-977. PMID: 33495238 -
J Immunol
IL-4 Treatment Mitigates Experimental Cerebral Malaria by Reducing Parasitemia, Dampening Inflammation, and Lessening the Cytotoxicity of T Cells. [Abstract]2021 Jan 1;206(1):118-131. PMID: 33239419 -
Front Oncol
2022 May 5;12:823377. PMID: 35600336 -
Mol Immunol
Role of uridine triggering M2 macrophage polarization to alleviate LPS-induced acute lung injury through the STAT6 signaling pathway. [Abstract]2026 May 23:195:198-208. PMID: 42176493 -
PLoS One
JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis. [Abstract]2026 Apr 9;21(4):e0341313. PMID: 41955245 -
Allergy Asthma Clin Immunol
The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway. [Abstract]2022 Feb 17;18(1):12. PMID: 35177102 -
Biochem Biophys Rep
Targeting STAT6 to mitigate sepsis-induced muscle atrophy and weakness: Modulation of mitochondrial dysfunction, ferroptosis, and CHI3L1-Mediated satellite cell loss. [Abstract]2023 Dec 16:37:101608. PMID: 38188367 -
Iran J Immunol
2024 Sep 25;21(3). PMID: 39319693 -
-
Solvente y solubilidad
DMSO : ≥ 35 mg/mL (87.97 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (31.42 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Normal human BSM cells (hBSMCs) are maintained in SmBM medium supplemented with 5% fetal bovine serum, 0.5 ng/mL human epidermal growth factor (hEGF), 5 μg/mL insulin, 2 ng/mL human fibroblast growth factor-basic (hFGF-b), 50 μg/mL gentamicin, and 50 ng/mL amphotericin B. Cells are maintained at 37°C in a humidified atmosphere (5% CO2), fed every 48 to 72 hours, and passaged when cells reached 90 to 95% confluence. Then the hBSMCs (passages 7-9) are seeded in 6-well plates and 8-well chamber slides at a density of 3,500 cells/cm2 and, when 80 to 85% confluence observed, cells are cultured without serum for 24 hours before addition of recombin is ant human IL-13. AS1517499 (100 nM) or its vehicle (0.3% DMSO) is treated 30 minutes before the addition of IL-13 (100 ng/mL). In some experiments, AS1517499 is treated 0 (co-incubation), 3, or 12 hours after the addition of IL-13. In another series of experiments, a selective Rho-kinase inhibitor Y-27632 (1 μM) or its vehicle (0.3% DMSO) is also applied 15 minutes before the IL-13 application. At the indicated time after the IL-13 treatment, cells are washed with PBS, immediately collected, and disrupted with 1× SDS sample buffer (250 μL/well), and used for Western blot analyses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
Male BALB/c mice are used. Preparation of a murine model of allergic bronchial asthma, which has an in vivo AHR, is performed. In brief, BALB/c mice (8 wk of age) are actively sensitized by intraperitoneal injections of 8 μg ovalbumin (OVA) with 2 mg Imject Alum on Day 0 and Day 5. The sensitized mice are challenged with aerosolized OVA-saline solution (5 mg/mL) for 30 minutes on Days 12, 16, and 20. A control group of mice received the same immunization procedure but inhaled saline aerosol instead of OVA challenge. The aerosol is generated with an ultrasonic nebulizer and introduced to a Plexiglas chamber box (130×200 mm, 100 mm height) in which the mice are placed. Animals also received intraperitoneal injection with AS1517499 (1 or 10 mg/kg/d; dissolved in 20% DMSO in saline) or its vehicle 1 hour before each antigen inhalation (Days 12, 16, and 20). Twenty-four hours after the last OVA challenge, mice are killed by exsanguination from abdominal aorta under urethane (1.6 g/kg, intraperitoneally) anesthesia.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Nagashima S, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1044-55. [Content Brief]
[2]. Chiba Y, et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009 Nov;41(5):516-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5134 mL | 12.5672 mL | 25.1345 mL | 62.8362 mL |
| 5 mM | 0.5027 mL | 2.5134 mL | 5.0269 mL | 12.5672 mL | |
| 10 mM | 0.2513 mL | 1.2567 mL | 2.5134 mL | 6.2836 mL | |
| 15 mM | 0.1676 mL | 0.8378 mL | 1.6756 mL | 4.1891 mL | |
| 20 mM | 0.1257 mL | 0.6284 mL | 1.2567 mL | 3.1418 mL | |
| 25 mM | 0.1005 mL | 0.5027 mL | 1.0054 mL | 2.5134 mL | |
| 30 mM | 0.0838 mL | 0.4189 mL | 0.8378 mL | 2.0945 mL | |
| 40 mM | 0.0628 mL | 0.3142 mL | 0.6284 mL | 1.5709 mL | |
| 50 mM | 0.0503 mL | 0.2513 mL | 0.5027 mL | 1.2567 mL | |
| 60 mM | 0.0419 mL | 0.2095 mL | 0.4189 mL | 1.0473 mL | |
| 80 mM | 0.0314 mL | 0.1571 mL | 0.3142 mL | 0.7855 mL |
AS1517499 Related Classifications
HY-100614 Related Classifications
Powered by Bioz